Biodelivery Sciences International INC: insider trades · United States · SEC (Form 4)

About Biodelivery Sciences International INC

BioDelivery Sciences International Inc. (BDSI) was a U.S.-based specialty pharmaceutical company that traded on the NASDAQ in the United States (United States). Originally founded in 1997 in Indiana and later reincorporated in Delaware in 2002, the company established its headquarters in Raleigh, North Carolina. Historically, BDSI focused on developing and commercializing therapies for patients living with chronic pain and related conditions, with an emphasis on unmet medical needs and differentiated drug-delivery formats. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1103021/000110302120000042/bdsi-20191231.htm?utm_source=openai)) The core of the business model centered on the company’s proprietary BEMA (BioErodible MucoAdhesive) technology, designed to deliver certain active ingredients through the oral mucosa in order to improve absorption and patient convenience. Its best-known products included BELBUCA (buprenorphine buccal film), BUNAVAIL, ELYXYB, and ONSOLIS, with a product portfolio primarily tied to pain management and adjacent therapeutic areas. BDSI commercialized its products mainly in the U.S. through its own sales force, while using third-party partnerships for certain non-U.S. commercialization activities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1103021/000110302121000029/bdsi-20201231.htm?utm_source=openai)) From a competitive standpoint, BDSI was a niche specialty pharma player rather than a broad diversified drug company. Its differentiation came from a combination of drug-delivery know-how, a focused pain portfolio, and targeted commercial execution. That also meant the company faced intense competition from larger pharmaceutical groups and other pain-focused companies, alongside material exposure to reimbursement dynamics, regulation, and litigation risks associated with the category. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1103021/000110302121000029/bdsi-20201231.htm?utm_source=openai)) Geographically, the company was primarily U.S.-centric, with the American market as the main revenue driver and only limited international reach through licensing or commercialization arrangements. On recent developments, the key fact for investors is that BioDelivery Sciences was acquired by Collegium Pharmaceutical in 2022, so it no longer operates today as an independent publicly traded company. For readers reviewing SEC Form 4 insider transactions or historical filings, BDSI should therefore be viewed as a legacy public issuer and acquisition case rather than an ongoing standalone NASDAQ-listed equity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1267565/000155837022001927/R27.htm?utm_source=openai))